ONSEMBLE mCRC

Clinical Programs

The ONSEMBLE phase 2 open-label randomized trial for the second line treatment of patients with KRAS/NRAS mutated metastatic colorectal cancer (MCRC) is designed to

  • Demonstrate onvansertib’s contribution to SoC
  • Confirm optimal dosing
  • Demonstrate onvansertib’s contribution to SoC
  • Operate with capital efficiency

Enrollment Criteria

ENDPOINTS

Primary
  • Objective Response Rate: CR + PR
Key Secondary
  • Progression-Free Survival
Other Secondary
  • Disease Control Rate: CR + PR + SD
  • Duration of Response: DoR
  • Overall Survival: OS
  • Reduced MAF association with ORR, PFS, DCR, DoR, OS